Who is moving to which position
Resolved 30 October 2026Departing officer
1 item“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
The company will implement a voluntary retirement program to optimise its organisational structure, appropriately reduce fixed costs and improve its earnings structure.
Concentration of management resources on the cell processing business; consolidation and review of research and development projects in the regenerative medicine products business; prioritisation of research and development activities; and optimisation of the organisational structure excluding the manufacturing division
| Item | Details |
|---|---|
| Resolution date | 30 October 2026 |
| Date of departure | 28 February 2027 (retirement date for voluntary retirees) |
| Name of departing officer | Applicants for voluntary retirement (approximately 20 positions, excluding the manufacturing division) |
| New position of departing officer | Retirement |
| Reason for change | The company will implement a voluntary retirement program to optimise its organisational structure, appropriately reduce fixed costs and improve its earnings structure. |
| Details of organizational changes | Concentration of management resources on the cell processing business; consolidation and review of research and development projects in the regenerative medicine products business; prioritisation of research and development activities; and optimisation of the organisational structure excluding the manufacturing division |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To concentrate management resources on the cell processing business and achieve improved profitability, a stronger financial base, improved company-wide performance and sustainable growth. The company determined that it would be difficult to pursue the development of regenerative medicine products in parallel with the cell processing business given its limited management resources, as the uncertainty involved in commercialising and monetising these products is high.